No current GLP-1 label lists psoriasis as an approved use, so prescribing one for it would be off-label. Phase 3b trial (Tirzepatide with ixekizumab): An open-label trial of adding tirzepatide to ixekizumab in people with psoriasis and overweight or obesity. At 36 weeks, 27.1% on both reached fully clear skin (PASI 100) and a 10% weight loss together, the main measure, against 5.8% on ixekizumab alone. Fully clear skin by itself was reached by 40.6% against 29.0%. It tested the combination, not tirzepatide alone. ClinicalTrials.gov lists 16 trials of these medicines on it: 0 with posted results and 4 recruiting now.
Read from the registry and PubMed every day. The newest update here is Nov 4, 2026.
Each read in the paper's abstract on Nov 6, 2026. Trials differ in who took part and how long they ran.
Tirzepatide with ixekizumab · 274 people · Better than the comparison · Open-label randomized trial
An open-label trial of adding tirzepatide to ixekizumab in people with psoriasis and overweight or obesity. At 36 weeks, 27.1% on both reached fully clear skin (PASI 100) and a 10% weight loss together, the main measure, against 5.8% on ixekizumab alone. Fully clear skin by itself was reached by 40.6% against 29.0%. It tested the combination, not tirzepatide alone.
A trial counts when the registry's conditions or title name this, and some study a related question, such as insulin sensitivity in people with the condition. A registered trial shows a question being asked, not that the answer is yes.
| Medicine | Trials | Posted results | Recruiting |
|---|---|---|---|
| Semaglutide | 6 | 0 | 2 |
| Tirzepatide | 6 | 0 | 2 |
| Liraglutide | 4 | 0 | 0 |
The registry page names each site and who can enroll. Ask your clinician before joining one.
| Trial | Medicine | Phase | Expected to finish |
|---|---|---|---|
| Effect of Semaglutide in Patients With Psoriasis and Obesity | Semaglutide | Phase 3 | Jan 31, 2027 |
| A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO) | Tirzepatide | Phase 4 | May 2028 |
| Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis | Semaglutide | Phase 4 | Feb 28, 2027 |
| Combination of Biologic and Anti-obesity Therapies in Psoriatic Arthritis | Tirzepatide | Not phased | May 2030 |
Systematic review · J Clin Med · Jul 1, 2026 · Marani A et al.
Randomized trial · JAMA Dermatol · Jul 1, 2026 · Lebwohl M et al. · cited by 17
Randomized trial · Arthritis Rheumatol · Mar 28, 2026 · Merola JF et al. · cited by 19
Listed from Europe PMC as published, newest first. A listing here is not a judgement of a study's quality or a recommendation.
Written from each source's own record as it changes. Every change on GLPcompare
Phase 3b trial (Tirzepatide with ixekizumab, 274 people): An open-label trial of adding tirzepatide to ixekizumab in people with psoriasis and overweight or obesity. At 36 weeks, 27.1% on both reached fully clear skin (PASI 100) and a 10% weight loss together, the main measure, against 5.8% on ixekizumab alone. Fully clear skin by itself was reached by 40.6% against 29.0%. It tested the combination, not tirzepatide alone.
Not in any current label we read. A prescriber can still use a medicine off-label, but insurance often limits coverage to approved uses, so ask your plan.
Semaglutide, with 6 registered trials on it, then Tirzepatide with 6. More trials do not mean better results: read what each posted.
4 trials are recruiting on ClinicalTrials.gov now, listed below with their registry pages, which name each site and who can enroll.